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General discussion 
Dear participants 
We are very happy to welcome you at the Research Meeting on Advances in Cancer Therapy. 
The meeting was initially intended to be just a small informal meeting of the radiotherapy 
group from Institute of Oncology, Ljubljana and medica! physics group from Jožef Stefan 
Insitute, Ljubljana. However, because of general interest, which we are very pleased about, 
we decided to organise a larger one. The high interest is also indication that more similar 
meetings should be organised and hopefully they would become regular practice of 
exchanging ideas. 
The meeting is organised in two large sections: medica! physics part and combined 
radiobiological/electroengineering/clinical part. Hopefully the variety of the presentations 
would stimulate even more fertile discussions and brainstorming. Even though very different 
in their approach both sections share a common goal - presenting ways to fight cancer more 
efficiently. Fighting cancer more efficiently is possible only if we understand it better, if we 
understand current methods of treatment and are familiar with the current research. If we 
manage to add just a small stone to the huge pile ofknowledge on cancer treatment today, this 
goal will be achieved. 
Enjoy the meeting! 
Robert Jeraj 
Božidar Casar 
List oj speakers 
Prof. dr. Marjan Budihna 
Position: Radiation Oncologist, Dept. of Radiotherapy, Institute of Oncology. Ljubljana, 
Slovenia 
Research interests: Head and neck radiotherapy, <lose-tirne relationship in Radiotherapy 
Address: 
Institute of Oncology, 
Zaloška 2, SI-1000 Ljubljana, Slovenia 
Tei: +386 61 13 14 225 
E-mail: mbudihna@onko-i.si
Božidar Casar, dipl. univ. fiz. 
Position: Radiophysicist, Dept. of Radiophysics, Institute of Oncology, Ljubljana, Slovenia 
Research interests: Stereotactic Radiosurgery, Quality Assurance, Dosimetry 
Address: 
Institute of Oncology 
Zaloška 2, SI-1000 Ljubljana, Slovenia 
Tei: +386 1 1319108 
E-mail: bcasar@onko-i.si
Dr. Martin Ebert 
Position: Senior Physicist, Sir Charles Gairdner Hospital, Perth, Australia 
Research interests: optimisation, radiobiology, stereotactic radiotherapy 
Address: 
Department ofRadiation Oncology, Sir Charles Gairdner Hospital 
Verdun Street, Nedlands, Westem Australia, Austarlia 6009 
Tei: +61 8 9346 1195 
Fax: +61 8 9346 3402 
E-mail: Martin.Ebert@health.wa.gov .au
Dr. Robert Jeraj 
Position: Research Assistant, Jožef Stefan Institute, Ljubljana, Slovenia 
Research interests: Monte Carlo transport, inverse treatment planning, optimisation 
Address: 
Jožef Stefan Institute 
Jamova 39, SI-1000 Ljubljana, Slovenia 
Tei: +386 1 5885 400 
Fax: +386 1 5612 335 
E-mail: robert.jeraj@ijs.si
Dr. Paul Keall 
Position: Physicist, Medica! College ofVirginia, Richmond, USA 
Research interests: Monte Carlo transport, optimisation, respiration gating 
Address: 
Medica! College ofVirgina, Box. 980058, Richmond 23298, USA 
Tei: + 1 804 628 0980 
Fax: + 1 804 828 6042 
E-mail: pjkeall@vcu.edu
Dr. Hotimir Lešničar 
Position: Medica! Director, Institute ofOncology, Ljubljana, Slovenia 
Research interests: radiotherapy 
Address: 
Institute of Oncology, 
Zaloška 2, SI-1000 Ljubljana, Slovenia 
Tei: +386 61 13 14 225 
E-mail: hlesnicar@onko-i.si
A/prof. Damijan Miklavčič 
Position: Head, Laboratory of biocybemetics, Faculty of electrical engineering, University of 
Ljubljana, Slovenia 
Research interests: biomedical engineering, effects of electric currents and EM fields on 
biological systems 
Address: 
Laborat01y of Biocybemetics 
Faculty of Electrical Engineering, University of Ljubljana 
Tržaška 25, SI-1000 Ljubljana, Slovenia 
Tel.: +386 61 1768 456 or 264 
Fax.: +386 61 126 46 58 or 30 
E-mail: damijan@svarun.fe.uni-lj.si
Dr. Srdjan Novakovič 
Position: Immunologist, Institute of Oncology, Ljubljana, Slovenia 
Research interests: biological therapies, tumor vaccines, tumor markers 
Address: 
Dept. ofTumor Biology, Institute ofOncology, 
Zaloška 2, SI-1000 Ljubljana, Slovenia 
Tei: +386 61 323 063 ext. 51-18 
E-mail: snovakovic@onko-i.si 
Mag. Vlado Robar 
Position: Medica! physicist, Institute of oncology, Ljubljana, Slovenia 
Research interests: Monte Carlo in radiotherapy, dosimetry 
Address: 
Institute of Oncology 
Zaloška 2, SI-1000 Ljubljana, Slovenia 
Tei: +386 1 1319108 
E-mail: vlado.robar@physics.onko-i.si
Prof. dr. Gregor Serša 
Position: Head, Dept. tumor biology, Institute of Oncology, Ljubljana, Slovenia 
Research interests: electrochemotherapy, radiobiology 
Address: 
Department ofTumor Biology, Institute ofOncology 
Zaloška 2, SI-1000 Ljubljana, Slovenia 
Tel/Fax: +386 1 433 74 10 
E-mail: gsersa@onko-i.si
Potential Therapeutic Gains with Gated Radiotherapy 
Paul Keall 
Department of Radiation Oncology 
Medica! College ofVirginia 
Richmond, USA 
Respiration motion in radiotherapy during imaging reduces the contrast, causes artifacts, and 
leads to less well-defined tumour and critical structure delineation. The size and position of 
the defined gross tumour volume (GTV) is uncertain, and therefore larger margins need to be 
added to construct the PTV. 
Gated radiotherapy uses a respiration-related measurement, such as chest wall motion, which 
is correlated with interna! anatomy motion. During both CT imaging and treatment, the beam 
is only on during a certain part of the breathing cycle, and therefore the position and size of 
the GTV is more reproducible. 
Gated radiotherapy can potentially reduce the size of the PTV without compromising the 
treatment. If a smaller volume is treated, treatment related complications will be reduced, 
and/or the dose can be increased to achieve greater tumour control. 
This talk will discuss both the potential gains with gated radiotherapy, and the gated imaging 
experience at the Medica! College ofVirginia. 









1 Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Western 
Australia, Australia 
2Department of Physics, University of Western Australia, Western Australia, Australia 
3Department of Physics, Queensland University ofTechnology, Queensland, Australia 
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Introduction The optimal choice of isotope and forn1 (i.e., wire, liquid etc) for endovascular 
brachytherapy depends on many factors including <lose uniformity across arterial structures, 
the influence of source centering, cost/availability, half-life and consideration of radiation 
protection. The centering issue was considered by calculating <lose distributions due to severa! 
sources, and examining the dose-area relationship for artery wall as sources are moved off­
centre. 
Material and methods Severa! sources currently being used in clinical trials were considered 
-
32P (wire), 192Ir (wire) and 188Re (in saline solution). EGS4 Monte Carlo was used with a 
cylindrical user-code in calculation of dose distributions around the various sources 
(assuming in a water-equivalent medium), and to obtain <lose fall-off curves with distance 
from the centre of each source. 
Two model arteries were considered, one with the lumen and artery wall concentric, and the 
other with assymetry present in both lumen and artery wall. The artery walls were broken up 
into multiple sectors, and <lose to these sectors due to an off-centre wire calculated using the 
Monte Carlo-derived <lose distributions. Dose-Area information was then derived from the 
resulting arterial dose distributions ( only 2D information was considered). This calculation 
was repeated for severa! off-axis positions of the two wire-based sources (see Table 1) to 
yield a series of dose-area hisotgrams (DAHs). For the solution-based source (
188Re), only a 
single DAH was obtained since the balloon used for irradiation with 188Re is self-centering. 
Results and discussion The results indicate the benefits for uniformity of using a y-emitting 
source, at the cost of increased dose to distal normal tissue. The y-emitting source has a 
slower <lose fall-off with resulting higher distal-doses. The �-emitters have a more rapid dose 
fall-off with a small bremsstrahlung tail past the maximum electron range. This more rapid 
<lose fall-off leads to a potentially broader range of doses to the artery wall when sources are 
not centred .This should be considered in light ofthe general inaccuracy associated with dose­
prescription in endovascular brachytherapy. 
BEAM: Radiation Therapy Modeling Tool 
Vlado Robar 
Institute of Oncology 
What is it? BEAM is a general purpose Monte Carlo code package that allows visual 
modeling of radiation therapy units, mostly linear accelerators. It is built on EGS4 code 
system and it runs on most Unix computers, with Linux being the platform of choice for low 
cost simulation. To run BEAM a Fortran F77 compiler is required (g77 recommended), 
whereas MORTRAN3, a preprocessor for Fortran is hidden in the code and average user is 
shielded from using it. Knowledge of MORTRAN3 is necessary only for development of 
new component modules. BEAM code can be efficiently run on networked computers or on 
parallel CPUs. 
What it does? BEAM code simulates radiation beams from any radiation therapy source, 
including low-energy x-rays, 6°Co beam and electron and photon beams from linear 
accelerators. BEAM models any radiation therapy source in detail by means of component 
modules (CM). CM is a simple 3D geometric object that can be fully described by a few 
parameters (e.g. a cylinder, a cone, a stack of cones). User can build a radiation therapy unit 
by putting together existing CMs (collimating jaws, mirrors, target, applicators) modeled 
individually. If needed one can develop new CMs. At the therapy unit exit window, radiation 
beam is represented in 5 dimensional phase-space. The dosimetric phantom may also be 
made of component modules, but a set of CT images can be employed for calculation of dose 
distribution in a phantom or patient. Even at the present stage of development, BEAM can 
function as an experimental 3D treatment planning system. 
How to get it? BEAM code is result of the OMEGA collaboration between National 
Research Centre (NRC) in Ottawa, Canada, and Madison University in Wisconsin. In order 
to get one's hands on the code, a course given at NRC has to be taken 
(http://www.irs.inms.nrc.ca/inms/irs/omega/brochure.html). Ali upcoming versions are Web­
distributed free of charge for the course attendants. 
What is its future? As computers becomes more powerful and cheaper, computing tirne for 
simulation is decreasing, which makes BEAM a capable tool for solving a wide range of 
dosimetric problems in radiation therapy. Calculations can be faster not only by using faster 
computers but also by improving computing algorithms, especially those for variance 
reduction. Future improvements of computer speed and further development of the code 
makes BEAM a firm ground for a 3D Monte Carlo treatment planning system. 
Reference: BEAM: A Monte Carlo code to simulate radiotherapy treatment units, D.W.O. Rogers et al., 
Med.Phys. 22 (5), May 1995 
Polystyrene phantom for simulation of stereotactic radiosurgery using 
radichromic films 
B. Casar(a), Z. Miloševič(b), B. Sekereš(a)
(a) Dept. ofRadiophysics, Institute ofOncology, Ljubljana, Slovenia
(b) C linica! institute for Radiology, Clinical Center, Ljubljana, Slovenia
Purpose: The aim of the study was to design and build polystyrene phantom appropriate for 
simulation of stereotactic radiosurgery, and to measure absorbed does distribution in three 
orthogonal planes through isocenter using radiochromic films 
Methods: A bullet shaped phantom contained 6 cm edge cube. A radiochromic film (Nuclear 
Associates, Div. of Victoreen) was placed in the middle of the cube in parallel to one of its 
planes. Phantom was scanned on the Siemens Somatom 4+ Ct in the sequence and the spiral 
mode. To mark the cube edges, angiographic catheters SF (french) were glued in cranio­
caudal direction orthogonal to transverse CT slices. After delineation of the target volume by 
neuroradiologist, a simple simulated treatment was performed with 5 MV philips SL-75/5 
linac. After location the tumor center, a dedicated tertiary collimator system (1) was used 
during simulation. Absorbed dose was measured in orthogonal planes through isocenter for 
three cube orientations . After three days, films were scanned with Multidata film 
densitometer (Multidata. corp). 
Results: Our phantom can be used for acquisition of quasi 3D information about dose 
distrubution. 
Conclusions: Relative simple yet precise absorbed dose measurements confirm that 
radiochromic films and our phantom can be used as a succesful tool for absorbed <lose 
verification. 
References: ( 1) Casar B, Tertiary collimator system for stereotactic radiosurgery with linear accelerator, Radio! 
Oncol 1998; 32( 1 ): 125-128 
Importance of accurate dose calculation in inverse treatment planning 
Robert Jeraj 




Most of the current inverse treatment planning algorithms use fast, but inaccurate dose 
calculation algorithms. As in conventional treatment planning, the use of such algorithms may 
lead into systematic errors in dose predictions of the order of a few percent. In inverse 
treatment planning a convergence error also appears because the inverse planning algorithm 
converges to the optimal solution for the inaccurate dose calculation, which is different from 
the optimal solution for the accurate dose calculation. In this work, both errors were identified 
and examined for three typical treatment sites: head and neck, lung and prostate. In addition, 
the biological significance ofthe errors was assessed. 
Three different dose calculation methods were used: Monte Carlo, convolution/ superposition 
and pencil beam. Monte Carlo-based inverse treatment planning algorithm (MCI) was 
modified to incorporate non-Monte Carlo dose calculation methods as well. The effect of 
different types of objective functions and hard constraints on the errors were examined. 
It was found that the systematic errors are not dependent on the objective functions, while the 
convergence errors express strong dependence. Typical standard deviations of systematic 
errors for the collapsed cone convolution dose calculations are 1-3% of Dmax (highest for head 
and neck) and standard deviations for the convergence errors are 3-8% of Dma,- This results in 
systematic tumour control probability (TCP)en-ors up to 4%, and convergence TCP errors up 
to 2%. Values and biological significance of errors for pencil beam-based inverse treatment 
planning were significantly higher. 
Effect of thermoradiotherapy: a consequence of direct or indirect 
radiosensitization 
H.Lešničar
Institute of Oncology, Zaloška c. 2, Ljubljana, SLOVENIA 
Introduction: Although, there are evidences supporting the direct radiosensitizing effect of 
hyperthermia (1), lately, some reports claimed that indirect radiosensitization (via enhanced 
oxygenation) is probably more important (2). The latter statement is based on randomized clinical 
trials <lata in which thermoradiotherapy showed definite advantage over radiotherapy alone, 
though, cumulative minimum intratumoral temperatures did not exceed 41 ° C. On the other hand, 
it was shown in controlled animal experiments that the enhancement of tumor oxygenation 
caused by "mild hyperthermia" can not last more than 1 O minutes after the heating (3). It is 
obvious that only the sequencing of the two therapies in which hyperthermia (HT) precedes 
radiotherapy (RT) should support the hypothesis of indirect radiosensitization. It was our aim to 
overview our clinical records of patients treated by thermoradiotherapy and to find some 
prognostic parameters which support one or another of above hypotheses. 
Material and methods: At the Institute of Oncology, Ljubljana, Slovenia 52 patients with 
locoregionaly inoperable malignant tumors were treated by thermoradiotherapy (TRT). Majority 
of patients were preiradiated. The cumulative total tumor <lose did not exceed 100 Gy. There 
were 29 patients in whom RT preceded HT, while in 23 patients RT immediately followed HT. 
Total tumor <lose of RT ranged from 20-70 Gy (median 60 Gy). In 28 patients an immediate 
fraction size >3 Gy was used concurrent with HT. Complete response (CR) rates and toxicity 
were evaluated according to intemationally established criteria. 
Results: In all 52 treated patients a CR rate of 60% was observed. Histology, tumor volume, 
minimum temperature, total tumor <lose, immediate fraction size of RT, and sequence of RT and 
HT were found to have a significant prognostic value. For 28 patients in whom minimum 
intratumoral temperature of 42.5°C was achieved and a fraction size of 2:: 3 Gy was applied 
immediately before HT a CR rate of 75% was observed. Late toxicity was more pronounced in 
patients in whom a cumulative tumor <lose of 2:: 85 Gy was applied. 
Conclusions: From our data it is obvious that only minimum intratumoral temperatures of 2:: 
42.5°C enabled an acceptable fina! treatment outcome. The effect of TRT was significantly 
pronounced in those treatments where heat was applied immediately after irradiation. With such a 
sequencing a hypothetical improvement of intratumoral oxygenation could not play a beneficial 
role. Therefore, our own clinical <lata speaks in favor of direct radiosensitizing effect of 
hyperthermia. 
References: 
l. Overgaard J, Gonzalez Gonzalez D, Hulshof MCCH, Arcangeli G, Dahi O, Mella O, Bentzen SM. Hyperthermia
as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized tria! by
European Society for Haperthermic Oncology. Int J Hyperthermia, 1996; 12: 3-20.
2. Oleson JR. Hyperthermia from the clinic to the laboratory: a hypothesis. Int J Hyperthermia, 1995; 11: 315-22.
3. Horsman MR, Overgaard J. Can mild hyperthermia improve tumor oxygenation? Int J Hyperthermia, 1997; 13:
141-7.
The treatment of advanced, inoperable sqamous celi carcinoma of the 
oropaharynx with radiotherapy and concomitant Mitomycin C and 
Bleomycin and some prognostic factors. 
M. Budihna, E. Šoba, L. Šmid, B. Zakotnik, H. Lešničar
Background. The incidence of the oropharyngeal squamous celi carcinoma in Slovenia is 
rapidly increasing, almost as fast as Jung cancer. More than 2/3 of patients referred to our 
institute are in an advanced stage. The results of the radiotherapy as a sole treatment were 
very poor: only 10% were cured. Therefore, concomitant chemotherapy was added to the 
conventional irradiation treatment. 
The aim of this study is to show the recurrence-free survival (RFS) according to some patient, 
tumour or chemoradiotherapy related parameters. 
Methods. From September 1990 to December 1997, 95 males and 3 females aged 37 - 70 
years (median 52,5 years) were treated for Stage III ( 21 pts.), IVa (64 pts.), and IVb (13 pts) 
squmous celi carcinoma of the oropharynx. The daily irradiation <lose was 1.8 Gy - 2 Gy 5 
times weekly, up to 
36 Gy - 78 Gy (median 68 Gy), the <lose of Mitomycin 15 mg / m2 was given on day 5 or 6, 
and 5 mg of Bleomycin 2 times weekly from the start of the treatment. The irradiation 
treatment was the same in both groups. Patients were randomized in the am1 without 
chemotherapy and the arm with chemotherapy only in the first 2 years. After 2 years of study 
the randomization was stop ped because of far better results in chemotherapy arm. 
Three patients received only paliative radiotherapy and were excluded from the study. 
The curves for RFS were done according to Kaplan-Mayer, the difference in RFS was 
calculated with logrank test. 




Observed parameter N RFS (%) at 7 years p 
Ali patients 95 53 -
T3 49 61 0.03 
T4 45 46 
N0-2a 43 71 
N2b-N2c 40 51 0.003 
N3 12 o 
Stage III 21 68 
IVa 61 58 0.006 
IVb 12 o 
Performance status (WHO) o 67 66 <0.0001 
1 or 2 28 22 
Treatment time <48 days 44 70 0.06 
;:,::43 days 51 44 
Tumour dose :::::68 Gy 56 62 0.06 
<68 Gy 39 42 
BED* (Gy) >67 65 60 0.02 
<67 30 38 
MitomycinC :::::28 mg 43 68 0.11 
<28mg 52 43 
Bleomycin :::::25 mg 49 62 0.06 
<25 mg 46 46 
*BED= biological effective dose
Toxic effects: Radiomucositis was more severe in patients in chemotherapy arm. In 
few patients the preplanned irradiation tumour dose and/or Bleomycin dose had to be 
reduced. There was no serious leukopenia or thrombopenia. Late effects were 
comparable in both groups. 
Conclusion 
The irradiation treatment with concomitant Mitomycin C and Bleomycin 1s an 
effective treatment for advanced oropharyngeal carcinoma. 
Tumor vaccines against malignant melanoma 
Srdjan Novakovic 
It has been widely recognized that cmTent adjuvant (post-surgical) therapies of cancer are not 
fully satisfactory mainly owing to the two globa! reasons: insufficient effectiveness and 
severe toxic side effects. In the past few years we have witnessed a rapid development of 
different biological and genetic therapies created to fight malignant diseases. These therapies 
have been designed to be more effective, more specific for tumor cells, and cause no or 
negligible toxic side effects. The most attractive current biological approach seems to be the 
creation of specific tumor vaccines. Severa! distinct ideas how to design a tumor vaccine were 
formed predominately to achieve: 1) enhanced production of various cytokines that 
participate in immune processes (IL-2, GM-CSF, IFN-y, TNF-a); 2) expression of allogeneic 
HLA antigens; 3) rep!acement of defective p53 genes, or 4) introduction of "suicide genes" 
into target ce!ls - genes that sensitize cells to drugs that are normally non-toxic for 
mammalian cells. Most of the mentioned propositions inc!ude a genetic manipulation (that 
favors some characteristics or processes capable of inducing the antitumor immune response) 
of autologous or homologous cells and usage of different non-viral or vira! vectors for gene 
transfer. However, there is stili some hesitation present when genetically manipulated 
constructs should be app!ied in humans. So our idea was to prepare and compare the 
effectiveness of two different vaccines against malignant melanoma: one prepared without 
utilizing foreign genetic material and another by inserting the gene of interest into syngeneic 
(autologous) tumor cells. The first approach proposes the creation oftumor vaccine by simple 
mixing of autologous - syngeneic sublethally irradiated B-16 melanoma tumor cells with 
pleiotropic biological response modifier - MVE-2 (maleic anhydride divinyl ether). The 
irradiated tumor cells are supposed to provide a sufficient quantity of tumor antigens, while 
the immunomodulator MVE-2 should at least multiply the number of cytotoxic macrophages 
that play a crucial role in the antitumor activity ofthe immune system together with CTL. By 
the second approach the HuTNF-a gene was ligated into the expression vector - pcDNA3 
plazmid and transferred into the syngeneic B-16 melanoma tumor cells. The transfected cells 
were then sublethally irradiated and used for vaccination of experimental animals. From the 
results it could be conc!uded that the effectiveness (i.e. tumor preventing potential) of the 
vaccine prepared without genetic manipulation is at Ieast comparable (if not superior) to the 
one of genetica!ly manipulated vaccine. Namely, the genetically manipulated tumor vaccine 
only prolonged the survival of vaccinated animals, while the vaccine containing irradiated 
syngeneic tumor cells and MVE-2, completely prevented tumor development in more than 
40% of prevaccinated animals challenged intraperitoneally with 5x105 viable tumor cells.
Moreover, the percentage oftumor-free animals (survivors) rose to as much as 90% when the 
application of this vaccine was repeated two weeks after the first vaccination. However, it has 
to be mentioned that the potentials of the genetically manipulated vaccine have not been fully 
determined so far since there are stili some essential experiments that remain to be carried out. 
Engineering Perspective of in vivo Electroporation 
Damijan Miklavčič 
Faculty of Electrical Engineering, University of Ljubljana 
Tržaška 25, 1000 Ljubljana, Slovenia 
E-mail: damijan@svarun.fe.uni-lj.si
Lluis M. Mir 
LPPMB, UMR 8532 CNRS, Institute Gustave-Roussy 
39 rue Camille Desmoulins, F-94805 VillejuifCedex, France 
E-mail: luismir@igr.fr
In the last two years, promising results for a new non-viral efficient gene therapy have been 
obtained in in vivo DNA electrotransfer studies [1-8]. It is also important to note that, 
recently, drug delivery using electric pulses has entered an active period of clinical trials [9-
13]. These two new therapeutical approaches are based on celi electropermeabilization, also 
tenned electroporation, a phenomenon where a transiently increased plasma membrane 
permeability is obtained after the cells were exposed to short and intense electrical pulses. 
Electropermeabilization thus allows otherwise nonpermeant molecules to enter the cytosol 
[14,15]. 
For effective drug delivery and gene transfection in vivo, the knowledge of electric field 
distribution is of utmost importance, to obtain an effective permeabilization as well as to 
maintain the viability of the electropenneabilized cells. Indeed, in order to achieve 
electropermeabilization in the tissue of interest, the magnitude of electric field intensity has to 
be above a critical threshold value [14,16,17], i.e. the reversible threshold. Furthermore, the 
magnitude of electric field intensity should not exceed the value which would produce 
irreversible damages to the plasma membrane, i.e. the irreversible threshold. Thus, the 
magnitude of electric field intensity should be high enough to cause reversible 
electropenneabilization but lower than the value causing irreversible damage [2,18]. The 
latter is the most critical for in vivo gene transfer but is also desirable in electrochemotherapy 
in order not to produce large instantaneous necrosis, which would result in massive tumour 
necrosis and possible exulceration and wound appearance. Moreover, for gene therapy, it has 
been recently reported [19] that, under relatively homogeneous exposure conditions [20], the 
optimal conditions for gene transfer correspond to the use of long pulses (20 milliseconds) at 
a voltage just necessary to obtain celi electropermeabilization, i.e. just above the reversible 
penneabilization threshold. Above the irreversible permeabilization threshold, when 
pennanent damages are inflicted to the plasma membrane, viability is !ost and efficacy of the 
DNA transfer is severely impaired [2]. Therefore it is necessary to determine (i) the electric 
field distribution in the target tissues, and (ii) the reversible as well as (iii) the irreversible 
permeabilization thresholds in order to use voltages and electrode geometries resulting in 
optimal exposure of the targeted tissue to electric fields intensities comprised between the two 
thresholds. 
Needle electrodes seem to be the most practical type of electrodes both for 
electrochemotherapy and gene therapy. However, the field generated by two or more needles 
is very inhomogeneous, as compared to the field distribution between two parallel plates. 
Nevertheless, it has been previously demonstrated that electric field distribution in the tissue 
can be controlled by the position ofthe electrodes in the tissue [21-23]. Therefore, control of 
electrode geometry and of pulse shape should allow to get the goals described here above, 
making electroporation quite safe and efficient both for electrochemotherapy and DNA 
electrotransfer. 
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lmprovement of combined modality therapy with cisplatin and radiation 
using electroporation of tumors 
GREGOR SERŠA, PH.D., SIMONA KRANJC, B.SC., ANO MAJA ČEMAŽAR, PH.D. 
Department ofTumor Biology, Institute of Oncology, Zaloška 2, 
SI-1000 Ljubljana, Slovenia 
Purpose: To evaluate whether local drug delivery method, i.e. electroporation of tumors, 
increases radiosensitizing effect of cisplatin. 
Materials and Methods: Subcutaneous EAT tumors in CBA mice were treated either by 
cisplatin, electric pulses or ionizing radiation. In electrochemotherapy protocol electric pulses 
were given to the tumor 3 min after intravenous injection of cisplatin. The interval between 
electrochemotherapy and irradiation was 20 min. Treatment effectiveness was evaluated by 
tumor growth delay and local tumor curability. 
Results: Electrochemotherapy of EAT tumors proved to be effective treatment, resulting in 
12% tumor cures, whereas treatment with cisplatin or electric pulses alone did not yield any 
tumor cures. As expected, injection of cisplatin 20 min prior to irradiation, increased 
radioresponse of tumors from 27% to 73% tumor cures. Electroporation of tumors also 
increased radiation response of tumors to 54% tumor cures. Electrochemotherapy given prior 
to irradiation increased radioresponsiveness oftumors, resulting in 92% tumor cures. 
Conclusions: This study shows that delivery of cisplatin into the cells by electroporation of 
tumors increases radiosensitizing effect of cisplatin. However, some effect may also be 
ascribed to application of electric pulses to the tumors that in our study also predisposed 
tumor cells to radiation damage. 
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